Clinical Trial: Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07780565) titled 'Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome' on Aug. 17.

Brief Summary: The goal of this clinical research study is to find the recommended dose of monzosertib in patients with relapsed/refractory AML and high-risk MDS. The safety and effects of monzosertib will also be studied.

Study Start Date: Jan. 01, 2027

Study Type: INTERVENTIONAL

Condition: Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome

Intervention: DRUG: Monzosertib

Give by mouth

DRUG: Posaconazole

Given by mouth

DRUG: Isavuconazole

Given by mouth

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer...